|
Gene: FGFR2 |
Gene summary for FGFR2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | FGFR2 | Gene ID | 2263 |
Gene name | fibroblast growth factor receptor 2 | |
Gene Alias | BBDS | |
Cytomap | 10q26.13 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P21802 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2263 | FGFR2 | CA_HPV_1 | Human | Cervix | CC | 8.51e-05 | -1.49e-01 | 0.0264 |
2263 | FGFR2 | CA_HPV_3 | Human | Cervix | CC | 1.97e-23 | 4.50e-01 | 0.0414 |
2263 | FGFR2 | CCI_1 | Human | Cervix | CC | 6.18e-03 | 6.82e-01 | 0.528 |
2263 | FGFR2 | CCI_2 | Human | Cervix | CC | 1.04e-03 | 6.95e-01 | 0.5249 |
2263 | FGFR2 | CCI_3 | Human | Cervix | CC | 2.01e-02 | 5.07e-01 | 0.516 |
2263 | FGFR2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.06e-04 | 4.09e-01 | -0.0811 |
2263 | FGFR2 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.15e-10 | 7.37e-01 | -0.1088 |
2263 | FGFR2 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.90e-02 | 5.56e-01 | -0.1526 |
2263 | FGFR2 | HTA11_866_2000001011 | Human | Colorectum | AD | 8.09e-11 | 5.73e-01 | -0.1001 |
2263 | FGFR2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.04e-03 | 4.46e-01 | -0.059 |
2263 | FGFR2 | HTA11_546_2000001011 | Human | Colorectum | AD | 6.24e-03 | 5.32e-01 | -0.0842 |
2263 | FGFR2 | A008-E-015 | Human | Colorectum | FAP | 1.76e-02 | 2.45e-01 | 0.0177 |
2263 | FGFR2 | CRC-1-8810 | Human | Colorectum | CRC | 2.86e-02 | -1.80e-01 | 0.6257 |
2263 | FGFR2 | AEH-subject1 | Human | Endometrium | AEH | 1.28e-05 | 3.41e-01 | -0.3059 |
2263 | FGFR2 | AEH-subject3 | Human | Endometrium | AEH | 2.22e-08 | 3.63e-01 | -0.2576 |
2263 | FGFR2 | AEH-subject5 | Human | Endometrium | AEH | 2.41e-14 | 5.35e-01 | -0.2953 |
2263 | FGFR2 | EEC-subject1 | Human | Endometrium | EEC | 2.50e-13 | 5.55e-01 | -0.2682 |
2263 | FGFR2 | EEC-subject2 | Human | Endometrium | EEC | 1.22e-25 | 6.67e-01 | -0.2607 |
2263 | FGFR2 | EEC-subject5 | Human | Endometrium | EEC | 1.43e-05 | 2.79e-01 | -0.249 |
2263 | FGFR2 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 4.88e-11 | 2.52e-01 | -0.1869 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00902636 | Cervix | CC | positive regulation of canonical Wnt signaling pathway | 22/2311 | 106/18723 | 9.52e-03 | 4.72e-02 | 22 |
GO:0030282 | Cervix | CC | bone mineralization | 24/2311 | 119/18723 | 1.00e-02 | 4.89e-02 | 24 |
GO:0110148 | Cervix | CC | biomineralization | 32/2311 | 171/18723 | 1.04e-02 | 4.97e-02 | 32 |
GO:0061351 | Cervix | CC | neural precursor cell proliferation | 28/2311 | 145/18723 | 1.04e-02 | 4.97e-02 | 28 |
GO:0048732 | Colorectum | AD | gland development | 149/3918 | 436/18723 | 6.07e-11 | 6.33e-09 | 149 |
GO:0030879 | Colorectum | AD | mammary gland development | 53/3918 | 137/18723 | 1.46e-06 | 4.58e-05 | 53 |
GO:0042060 | Colorectum | AD | wound healing | 128/3918 | 422/18723 | 2.73e-06 | 7.89e-05 | 128 |
GO:0030111 | Colorectum | AD | regulation of Wnt signaling pathway | 102/3918 | 328/18723 | 8.51e-06 | 2.03e-04 | 102 |
GO:0016055 | Colorectum | AD | Wnt signaling pathway | 130/3918 | 444/18723 | 1.60e-05 | 3.37e-04 | 130 |
GO:0198738 | Colorectum | AD | cell-cell signaling by wnt | 130/3918 | 446/18723 | 2.02e-05 | 4.10e-04 | 130 |
GO:0001701 | Colorectum | AD | in utero embryonic development | 110/3918 | 367/18723 | 2.36e-05 | 4.62e-04 | 110 |
GO:0046777 | Colorectum | AD | protein autophosphorylation | 74/3918 | 227/18723 | 2.48e-05 | 4.76e-04 | 74 |
GO:0007409 | Colorectum | AD | axonogenesis | 122/3918 | 418/18723 | 3.36e-05 | 6.15e-04 | 122 |
GO:0001890 | Colorectum | AD | placenta development | 51/3918 | 144/18723 | 3.99e-05 | 7.16e-04 | 51 |
GO:0001892 | Colorectum | AD | embryonic placenta development | 33/3918 | 82/18723 | 5.30e-05 | 9.01e-04 | 33 |
GO:0061564 | Colorectum | AD | axon development | 132/3918 | 467/18723 | 8.40e-05 | 1.31e-03 | 132 |
GO:0061180 | Colorectum | AD | mammary gland epithelium development | 28/3918 | 67/18723 | 8.74e-05 | 1.35e-03 | 28 |
GO:0033674 | Colorectum | AD | positive regulation of kinase activity | 131/3918 | 467/18723 | 1.28e-04 | 1.85e-03 | 131 |
GO:0022612 | Colorectum | AD | gland morphogenesis | 42/3918 | 118/18723 | 1.62e-04 | 2.23e-03 | 42 |
GO:0060070 | Colorectum | AD | canonical Wnt signaling pathway | 90/3918 | 303/18723 | 1.76e-04 | 2.38e-03 | 90 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa0401512 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa052157 | Cervix | CC | Prostate cancer | 27/1267 | 97/8465 | 7.54e-04 | 3.39e-03 | 2.01e-03 | 27 |
hsa040142 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa0523010 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa0481017 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa0401513 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0521512 | Cervix | CC | Prostate cancer | 27/1267 | 97/8465 | 7.54e-04 | 3.39e-03 | 2.01e-03 | 27 |
hsa0401411 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
hsa0401012 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa0523013 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa05230 | Colorectum | AD | Central carbon metabolism in cancer | 33/2092 | 70/8465 | 3.61e-05 | 3.19e-04 | 2.03e-04 | 33 |
hsa04015 | Colorectum | AD | Rap1 signaling pathway | 71/2092 | 210/8465 | 1.72e-03 | 9.68e-03 | 6.18e-03 | 71 |
hsa04810 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
hsa05215 | Colorectum | AD | Prostate cancer | 35/2092 | 97/8465 | 7.95e-03 | 3.13e-02 | 2.00e-02 | 35 |
hsa01521 | Colorectum | AD | EGFR tyrosine kinase inhibitor resistance | 29/2092 | 79/8465 | 1.15e-02 | 4.24e-02 | 2.71e-02 | 29 |
Page: 1 2 3 4 5 6 7 8 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Cervix | ADJ |
FGF1 | FGFR2 | FGF1_FGFR2 | FGF | Cervix | CC |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Cervix | CC |
FGF2 | FGFR2 | FGF2_FGFR2 | FGF | CRC | ADJ |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | CRC | CRC |
FGF2 | FGFR2 | FGF2_FGFR2 | FGF | Endometrium | ADJ |
FGF2 | FGFR2 | FGF2_FGFR2 | FGF | Endometrium | AEH |
FGF2 | FGFR2 | FGF2_FGFR2 | FGF | Endometrium | EEC |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Endometrium | EEC |
FGF1 | FGFR2 | FGF1_FGFR2 | FGF | HNSCC | OSCC |
FGF2 | FGFR2 | FGF2_FGFR2 | FGF | HNSCC | OSCC |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | HNSCC | OSCC |
FGF18 | FGFR2 | FGF18_FGFR2 | FGF | HNSCC | OSCC |
FGF2 | FGFR2 | FGF2_FGFR2 | FGF | HNSCC | Precancer |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | HNSCC | Precancer |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Lung | AAH |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Lung | ADJ |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Lung | AIS |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Lung | IAC |
FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Lung | Precancer |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FGFR2 | SNV | Missense_Mutation | rs779423644 | c.364G>A | p.Val122Met | p.V122M | P21802 | protein_coding | deleterious(0.01) | possibly_damaging(0.902) | TCGA-3C-AALJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
FGFR2 | SNV | Missense_Mutation | c.338N>C | p.Val113Ala | p.V113A | P21802 | protein_coding | tolerated(0.52) | benign(0.1) | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
FGFR2 | SNV | Missense_Mutation | c.1763N>G | p.Ser588Cys | p.S588C | P21802 | protein_coding | tolerated(0.31) | possibly_damaging(0.857) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
FGFR2 | SNV | Missense_Mutation | c.785N>C | p.Leu262Pro | p.L262P | P21802 | protein_coding | deleterious(0.01) | probably_damaging(0.937) | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FGFR2 | SNV | Missense_Mutation | novel | c.1904N>C | p.Val635Ala | p.V635A | P21802 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FGFR2 | SNV | Missense_Mutation | rs121913474 | c.1147T>C | p.Cys383Arg | p.C383R | P21802 | protein_coding | deleterious(0.02) | possibly_damaging(0.865) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FGFR2 | SNV | Missense_Mutation | c.1650T>G | p.Asn550Lys | p.N550K | P21802 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FGFR2 | SNV | Missense_Mutation | c.1099N>C | p.Glu367Gln | p.E367Q | P21802 | protein_coding | tolerated(0.19) | benign(0.156) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
FGFR2 | SNV | Missense_Mutation | rs121913476 | c.1650T>A | p.Asn550Lys | p.N550K | P21802 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide+tamoxifen | SD |
FGFR2 | SNV | Missense_Mutation | c.1414G>T | p.Asp472Tyr | p.D472Y | P21802 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A14W-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Chemotherapy | cytoxan | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | AZ6089 | 22869148 | ||
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | CVBT-141H | |||
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | BGJ398 | INFIGRATINIB | |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | DOVITINIB | DOVITINIB | ||
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | 252827519 | ||
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | TRAFERMIN | TRAFERMIN | ||
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | NINTEDANIB | NINTEDANIB | |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | Trametinib | TRAMETINIB | 27338794 | |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | CHEMBL1852688 | INFIGRATINIB | |
2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | LENVATINIB | LENVATINIB |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |